BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17362772)

  • 1. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R
    Transplantation; 2009 Apr; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H; Froidure A; Dandavino R; Daloze P; Hébert MJ; Colette S; Boucher A
    Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
    Diekmann F; Budde K; Slowinski T; Oppenheimer F; Fritsche L; Neumayer HH; Campistol JM
    Transpl Int; 2008 Feb; 21(2):152-5. PubMed ID: 18005087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V; Abraham G; Fathima N; Sundaram V; Reddy YN; Mathew M; Sathiah V
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.
    Ayub-Ferreira SM; Avila MS; Feitosa FS; Souza GE; Mangini S; Marcondes-Braga FG; Issa VS; Bacal F; Chizzola PR; Cruz FD; Bocchi EA
    Transplant Proc; 2010 Mar; 42(2):542-4. PubMed ID: 20304188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
    Gutiérrez MJ; González E; Andrés A; Morales JM
    Transplant Proc; 2009; 41(6):2348-50. PubMed ID: 19715916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.